The FDA granted a fast track designation to the highly-selective N-terminal domain inhibitor EPI-7386 for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who are resistant to standard-of-care options, according to an announcement from ESSA Pharma Inc.
As the impact of the coronavirus disease 2019 (COVID-19) pandemic lingers into the later part of 2020, consideration is needed regarding the lasting effects on patients with cancer who may have experienced delayed care or diagnosis.
Nurses play a key role in ensuring that patients with gynecologic cancer understand the results and implications of genetic testing.
Chemotherapy agents are excreted through urine and feces, and a recent study found that both patient and staff bathrooms were contaminated.
The FDA has granted a breakthrough therapy designation to plinabulin for chemotherapy-induced neutropenia (CIN).
While EMRs have improved clinician workflow in recent years, they are not perfect. Paper charts may still have a place in cancer clinical research.
The FDA has approved copper Cu 64 dotatate injection (Detectnet) for the localization of somatostatin receptor–positive neuroendocrine tumors (NETs), according to an announcement from RadioMedix Inc. and Curium Pharma.
Oncology nurses often face incivility from their peers, but there are methods they can use to combat the stress of a toxic work environment.
There is currently no way to measure chemotherapy-induced peripheral neuropathy in pediatric patients, but a team of nurse researchers are developing a new tool to meet this need.
As nurses navigate cancer care during the COVID-19 pandemic, it is especially important that they have their voices heard – and their votes counted.
The FDA has issued an alert to professionals, investigators, and patients that the phase 3 IMpassion131 trial (NCT03125902) failed to show the effectiveness of atezolizumab (Tecentriq) plus paclitaxel in treatment-naïve patients with inoperable locally advanced or metastatic triple-negative breast cancer.
Frontline workers need self care now more than ever.
The novel coronavirus disease (COVID-19) continues to impact the care of patients with metastatic renal cell carcinoma (mRCC) and other cancers in a multitude of ways, according to Toni K. Choueiri, MD, but those working in the field of oncology are rising up to the challenge by learning as much as possible about the virus to make the best treatment decisions possible for their patients.
Blinatumomab (Blincyto) monotherapy as consolidation therapy prior to allogeneic hematopoietic stem cell transplant (HSCT) resulted a significant improvement in event-free survival (EFS) and a lower risk of recurrence in children with high-risk B-cell precursor (BCP­)–acute lymphoblastic leukemia (ALL).
The orally available belumosudil continues be promising in patients with chronic graft-versus-host disease (cGVHD) who have received 2 or more prior lines of systemic therapy
The Food and Drug Administration (FDA) approved pralsetinib (Gavreto) for the treatment of patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC), according to Genentech, the co-manufacturer of the drug.
The PARP inhibitor rucaparib was beneficial and tolerable for patients with BRCA-positive, metastatic, castration-resistant prostate cancer.
The Centers for Medicare & Medicaid Services may expand telemedicine and home healthcare access. However, ASCO warned them of the dangers of in-home chemotherapy infusions.
The management of metastatic colorectal cancer (mCRC) continues to become more personalized, with care decisions being based on factors ranging from the patient’s primary tumor location, to performance status, to the presence of specific mutations, according to Axel Grothey, MD, and novel approaches emerging in later lines are helping to further improve outcomes.
We asked our audience about how the COVID-19 pandemic changed nursing school. Here’s what some of them had to say.
The FDA has granted a priority review to a new drug application for oral paclitaxel and encequidar for use in patients with metastatic breast cancer.
The FDA has approved CC-486 for the continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy who are not able to complete intensive curative therapy.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from August 2020.
The NCI and Cancer Research UK are coming together to improve cancer care around the world.
Denise A. Yardley, MD, highlights the evolving role of adjuvant CDK4/6 inhibition in HR-positive metastatic breast cancer.
To effectively tailor treatment for transplant-ineligible patients with multiple myeloma in the frontline setting, factors such as frailty status must be taken into consideration, according to Smith Giri, MD, MHS.
Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.
The COVID-19 pandemic can affect every stage of the cancer experience: from diagnosis to adverse event management.
The FDA has approved the FoundationOne Liquid CDx, a liquid biopsy for all solid tumors with multiple companion diagnostic indications.
The FDA has approved a generic form of pemetrexed for intravenous administration as a single-agent in patients with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) that has not progressed following 4 cycles of first-line platinum-based chemotherapy.
